Bifidobacterium pseudocatenum strain B24790 with functions of inhibiting clinical multi-drug-resistant bacteria and resisting inflammation and application of bifidobacterium pseudocatenum strain B24790

Abstract

The invention provides a Bifidobacterium pseudocatenatum (Bifidobacterium pseudocatenatum) strain B24790 with the functions of inhibiting clinical multi-drug-resistant bacteria and resisting inflammation and application of the Bifidobacterium pseudocatenatum strain B24790, and belongs to the technical field of functional microorganisms. The invention discloses a bifidobacterium pseudocatenum strain B24790, and the preservation number of the bifidobacterium pseudocatenum strain B24790 is GDMCC No: 65515. The strain B24790 has good bacteriostatic activity on clinical multi-drug-resistant pathogenic bacteria such as clostridium difficile, acinetobacter baumannii HRAB-85, drug-resistant staphylococcus aureus, drug-resistant escherichia coli and pseudomonas aeruginosa PAO1, and also has a good anti-inflammatory effect. The strain B24790 is human-derived, has good gastrointestinal fluid resistance, and has the potential of colonization of human bodies. The bifidobacterium pseudocatenum strain B24790 provided by the invention has certain advantages in the aspects of drug-resistant bacterium infection and inflammatory diseases, can be used for preparing related products, and has a wide market prospect.

Description

Technical Field

[0001] The invention belongs to the technical field of functional microorganisms, and specifically relates to a Bifidobacterium pseudocatenulatum strain B24790 with the functions of inhibiting clinical multidrug-resistant bacteria and anti-inflammatory and an application thereof. Background Art

[0002] Multidrug-resistant organisms (MDR) refer to bacteria that are resistant to three or more types of clinically used antimicrobial drugs. These bacteria have developed resistance to a variety of commonly used antibiotics such as penicillin, erythromycin, cephalosporins, etc., which makes the treatment of multidrug-resistant infections very difficult. Symptoms of infection caused by multidrug-resistant bacteria include inflammation, persistent high fever, septic shock, etc., and more sensitive antibiotics are needed for treatment, but this will cause pathogens to become resistant to more and more antibiotics, gradually evolving into super-resistant bacteria, which brings increasing challenges to clinical treatment. Therefore, finding safer, more effective and economical treatment methods is the key to clinical response to diseases caused by multidrug-resistant infections.

[0003] In recent years, multiple medicaments against multi-drug resistant bacteria have emerged, mainly including probiotics, oligosaccharides, antimicrobial peptides, enzyme preparations, Chinese herbal medicine preparations and acidulants, among which probiotics are widely concerned because of their unique advantages. Probiotics are a class of microorganisms that are beneficial to human health and play an important role in maintaining human health. The microorganism currently reported for suppressing clinical multi-drug resistant bacteria is a lactic acid bacteria strain, for example including plant lactobacillus GS083, plant lactobacillus GS086, plant lactobacillus GS090 and fermented lactobacillus GF110 (CN111534452A). There is no report about bifidobacterium having the activity of suppressing clinical multi-drug resistant bacteria. Summary of the invention

[0004] In view of this, the object of the present invention is to provide a Bifidobacterium pseudocatenulatum strain B24790, which has the function of inhibiting clinical multidrug-resistant bacteria.

[0005] The invention provides a Bifidobacterium pseudocatenulatum strain B24790, with a preservation number of GDMCC No: 65515.

[0006] The present invention provides a metabolite or culture of the Bifidobacterium pseudocatenulatum strain B24790.

[0007] The present invention provides a method for preparing the metabolites of the Bifidobacterium pseudocatenulatum strain B24790, comprising the following steps:

[0008] The activated Bifidobacterium pseudocatenulatum strain B24790 is inoculated into MPYG liquid medium for anaerobically culturing to obtain a culture;

[0009] The liquid phase was separated from the culture to obtain metabolites of Bifidobacterium pseudocatenulatus strain B24790.

[0010] Preferably, after separating the liquid phase, the liquid phase is further concentrated; the concentration multiple is 5 to 10 times.

[0011] The present invention provides a probiotic, comprising the Bifidobacterium pseudocatenulatum strain B24790, the metabolite or the culture or the metabolite of the Bifidobacterium pseudocatenulatum strain B24790 prepared by the preparation method.

[0012] The present invention provides use of the Bifidobacterium pseudocatenulatum strain B24790, the metabolite or the culture or the metabolite of the Bifidobacterium pseudocatenulatum strain B24790 prepared by the preparation method in preparing a product for inhibiting clinical drug-resistant bacteria.

[0013] Preferably, the clinical drug-resistant bacteria include at least one of the following: Clostridium difficile, Acinetobacter baumannii, Pseudomonas aeruginosa, drug-resistant Staphylococcus aureus and Escherichia coli.

[0014] Preferably, the product includes at least one of the following: medicine, disinfected daily necessities, food, food additives, feed or feed additives.

[0015] The present invention provides use of the Bifidobacterium pseudocatenulatum strain B24790, the metabolite or the culture or the metabolite of the Bifidobacterium pseudocatenulatum strain B24790 prepared by the preparation method in preparing anti-inflammatory drugs.

[0016] Preferably, the anti-inflammatory drug comprises at least one of the following dosage forms: tablets, powders, granules, capsules and oral solutions.

[0017] The present invention provides a pseudo-chain Bifidobacterium strain B24790, with a deposit number of GDMCCNo: 65515. The pseudo-chain Bifidobacterium strain B24790 provided by the present invention has good antibacterial activity against clinical multi-drug resistant pathogens such as Clostridium difficile, Acinetobacter baumannii HRAB-85, Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa PAO1, and can significantly reduce the release levels of IL-6 and TNF-α in LPS-induced RAW 264.7 cells, and has a good anti-inflammatory effect. In addition, the pseudo-chain Bifidobacterium strain B24790 is isolated from the intestinal flora of healthy people, has good resistance to gastrointestinal fluid, and has the potential to colonize the human body. Therefore, the pseudo-chain Bifidobacterium strain B24790 provided by the present invention has certain advantages in treating drug-resistant bacterial infections and inflammatory diseases, and the strain can be used to prepare probiotic preparations, etc., and has broad market prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 The colony morphology (left) and Gram staining microscopy results (right) of strain B24790;

[0019] Figure 2 This is the phylogenetic tree of strain B24790;

[0020] Figure 3 It is the blank control test result of in vitro inhibition of clinical multi-drug resistant bacteria;

[0021] Figure 4 The results of the in vitro test of the ability of strain B24790 to inhibit clinical multi-drug resistant bacteria;

[0022] Figure 5 The results of antibiotic sensitivity test for strain B24790;

[0023] Figure 6 The results are the test results of the effect of strain B24790 on LPS-induced IL-6 secretion by RAW264.7 cells;

[0024] Figure 7 These are the test results of the effect of strain B24790 on LPS-induced TNF-α secretion in RAW264.7 cells.

[0025] Biomaterial Deposit Information

[0026] Bifidobacterium pseudocatenulatum strain B24790 was deposited in the Guangdong Provincial Microbiological Culture Collection Center on November 21, 2024, with the unit abbreviation GDMCC, the address is 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, Guangdong Institute of Microbiology, and the deposit number is GDMCC No: 65515. DETAILED DESCRIPTION

[0027] The invention provides a Bifidobacterium pseudocatenulatum strain B24790, with a preservation number of GDMCC No: 65515.

[0028] In the present invention, the strain B24790 is isolated and screened from the feces of healthy and long-lived elderly people. The colony characteristics of the B24790 strain are: the colony surface is smooth, the edges are neat, the colony is white and round, it is a single colony, it is rod-shaped under a microscope, it has no spores, and it is Gram-positive. Molecular identification, the 16S rDNA sequence of the strain B24790 is shown in SEQ ID NO: 1. Based on the morphological characteristics and molecular identification, the B24790 was identified as Bifidobacterium pseudosphenoides.

[0029] The present invention provides a metabolite or culture of the Bifidobacterium pseudocatenulatum strain B24790.

[0030] In the present invention, the culture contains the bacterial body of Bifidobacterium pseudocatenulatum strain B24790 and the metabolites of Bifidobacterium pseudocatenulatum strain B24790.

[0031] The present invention provides a method for preparing the metabolites of the Bifidobacterium pseudocatenulatum strain B24790, comprising the following steps:

[0032] The activated Bifidobacterium pseudocatenulatum strain B24790 is inoculated into MPYG liquid medium for anaerobically culturing to obtain a culture;

[0033] The liquid phase was separated from the culture to obtain metabolites of Bifidobacterium pseudocatenulatus strain B24790.

[0034] In the present invention, the anaerobic culture preferably includes anaerobic culture at 36-38°C for 16-20h, and can be anaerobic culture at 37°C for about 18h. The inoculation amount of the inoculation is preferably 5%-8%, and can be 6%. The activation method of the pseudo-small chain Bifidobacterium strain B24790 is preferably to streak culture the frozen pseudo-small chain Bifidobacterium strain B24790 using the plate streak method, and pick a single colony and inoculate it in MPYG liquid culture medium for anaerobic culture. The streak culture time is 1-2d. The method of separating the liquid phase is preferably centrifugation and filtration. The speed of the centrifugation is preferably 8000-12000rpm, and can be 10000rpm. The centrifugation time is preferably 4-6min, and can be 5min. The filtration method is preferably membrane filtration. The pore size of the filter membrane is preferably 0.22μm. After collecting the liquid phase, it is preferably also concentrated. The concentration method preferably includes freeze drying. The multiple of the concentration is 5-10 times, and can be 6-8 times, and can also be 7 times.

[0035] The present invention provides a probiotic, comprising the Bifidobacterium pseudocatenulatum strain B24790, the metabolite or the culture or the metabolite of the Bifidobacterium pseudocatenulatum strain B24790 prepared by the preparation method.

[0036] In the present invention, the probiotic preferably includes at least one of the following dosage forms: aqueous solution, powder and granule. The effective live bacteria concentration of the Bifidobacterium pseudocatenulatum strain B24790 is not less than 1×10 8 CFU / mL, can be 5×10 8 CFU / mL, 10×10 8 CFU / mL, 50×10 8 CFU / mL, 100×10 8 CFU / mL, 500×10 8 CFU / mL. The effective concentration of the metabolite or culture is not less than 10% to 99%, can be 15% to 80%, can also be 20% to 70%, can also be 30% to 50%. The present invention has no special restrictions on the preparation method of the probiotics, and the probiotic preparation method known in the art can be used.

[0037] The present invention provides use of the Bifidobacterium pseudocatenulatum strain B24790, the metabolite or the culture or the metabolite of the Bifidobacterium pseudocatenulatum strain B24790 prepared by the preparation method in preparing a product for inhibiting clinical drug-resistant bacteria.

[0038] In the present invention, the clinical drug-resistant bacteria preferably include at least one of the following: Clostridium difficile, Acinetobacter baumannii, Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The Acinetobacter baumannii is represented by Acinetobacter baumannii HRAB-85. The Staphylococcus aureus is represented by resistant Staphylococcus aureus MRSA. The Escherichia coli is represented by resistant Escherichia coli producing ESBL. The Pseudomonas aeruginosa is represented by resistant Pseudomonas aeruginosa PAO1.

[0039] In the embodiment of the present invention, the metabolites of the pseudocatenarian Bifidobacterium strain B24790 were used to carry out in vitro antibacterial experiments, and the results showed that the metabolites had good antibacterial effects on Acinetobacter baumannii HRAB-85, resistant Staphylococcus aureus, resistant Escherichia coli, Pseudomonas aeruginosa PAO1 and Clostridium difficile, among which the antibacterial activity against Clostridium difficile and resistant Staphylococcus aureus was the strongest. This shows that the pseudocatenarian Bifidobacterium strain B24790 exerts its in vitro antibacterial activity by secreting antibacterial metabolites.

[0040] In the present invention, the product preferably includes at least one of the following: medicine, disinfection daily necessities, food, food additives, feed or feed additives. The medicine preferably includes oral medicine or external medicine. The dosage form of the oral medicine is preferably tablets, powders, granules, capsules and oral liquids. The external medicine preferably includes sprays, ointments, patches, etc. The disinfection daily necessities preferably include disinfectant sprays, disinfectant hand gels, disinfectant detergents, etc. The preparation of the food additives, feed additives, food or feed is conducive to the antibacterial effect of Bifidobacterium pseudomicrocystis strain B24790 and its metabolites to inhibit the growth of pathogenic and drug-resistant bacteria in food or feed. The effective live bacterial concentration of Bifidobacterium pseudomicrocystis strain B24790 in the product is not less than 1×10 8 CFU / mL, can be 5×10 8 CFU / mL, 10×10 8 CFU / mL, 50×10 8 CFU / mL, 100×10 8 CFU / mL, 500×10 8 CFU / mL. The effective concentration of the metabolite or culture is not less than 10% to 99%, can be 15% to 80%, can also be 20% to 70%, can also be 30% to 50%. The present invention has no special restrictions on the preparation method of the product, and the method well known in the art can be used.

[0041] The present invention provides use of the Bifidobacterium pseudocatenulatum strain B24790, the metabolite or the culture or the metabolite of the Bifidobacterium pseudocatenulatum strain B24790 prepared by the preparation method in preparing anti-inflammatory drugs.

[0042] In the present invention, the anti-inflammatory drug preferably includes at least one of the following dosage forms: tablets, powders, granules, capsules and oral liquids. The present invention has no particular limitation on the preparation method of the anti-inflammatory drug, and any method known in the art can be used.

[0043] In the present embodiment, a cell-level anti-inflammatory experiment was carried out, using the LPS-induced RAW 264.7 cell inflammation model as the experimental object, and the pro-inflammatory factors in the LPS-stimulated RAW 264.7 cell culture fluid increased significantly, while the pseudo-catenarian Bifidobacterium strain B24790 could significantly reduce the level of pro-inflammatory factors in the RAW 264.7 cells stimulated by LPS. This result shows that the pseudo-catenarian Bifidobacterium strain B24790 has the potential to inhibit inflammation.

[0044] The following is a detailed description of the Bifidobacterium pseudocatenulatum strain B24790 with the functions of inhibiting clinical multi-drug resistant bacteria and anti-inflammatory and its application provided by the present invention in conjunction with the embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0045] The culture medium involved in the embodiment is as follows:

[0046] MPYG solid culture medium: 5g tryptone, 3g peptone, 2g soy peptone, 1g polypeptone, 10g yeast extract, 5g beef extract, 5g glucose, 0.5g maltose, 0.5g cellobiose, 0.5g soluble starch, 2g dipotassium hydrogen phosphate, 0.5g cysteine, 0.25g sodium sulfide, 1mg resazurin, 0.5mL Tween 80, 0.5mL glycerol, 1000mL distilled water, pH = 6.6-6.8. When preparing the solid culture medium, add 15g agar and sterilize under high pressure at 121℃ for 20min.

[0047] LB medium: 10 g of tryptone, 5 g of yeast extract, 10 g of NaCl, 1000 mL of distilled water, pH = 7.0 ± 0.1. When preparing solid culture medium, add 15 g of agar and sterilize at 121°C for 20 min.

[0048] Example 1

[0049] Isolation, purification and identification of Bifidobacterium pseudocatenulatum strain B24790

[0050] (1) Strain isolation and purification: 0.1 g of centenarian fecal sample was added to 0.9 mL of sterile saline, and the sample suspension was obtained by vortexing and mixing. The sample suspension was diluted 10-fold with saline to obtain 10 -1 ~10 -5 The dilution series was 10 -3 ~10 -5 Take 0.1mL of the dilution and apply it to MPYG solid medium, and culture it anaerobically at 37℃ for 1-2 days. After the culture, select the target strain according to the morphological characteristics of the colony, purify the strain by streaking on the plate, and culture it anaerobically for 1-2 days to obtain a strain numbered B24790. The plate colony picture is as follows Figure 1 As shown, the colony surface of strain B24790 is smooth, milky white, rod-shaped, spore-free, and Gram-positive. A single colony on the purification plate was picked and inoculated into MPYG liquid medium. After anaerobic culture at 37°C for about 18 hours, the bacterial solution was mixed with 40% glycerol at a ratio of 1:1 and stored in a -80°C refrigerator.

[0051] (2) Identification of strain 16S rDNA: After separation and purification, pick the colonies and mix them in 30 μL PBS (10 mmol / L, pH = 7.4) buffer to make a bacterial suspension. Take 1 μL of the bacterial suspension and add it to the 16S rDNA amplification system. The 50 μL amplification system is as follows: 1 μL of the bacterial suspension as the template, 1 μL of primer 27F (SEQ ID NO: 2) and primer 1492R (SEQ ID NO: 3), 25 μL of 2×Es Taq Mix, dd H 2 Figure 2 As shown. The B24790 strain is most closely related to Bifidobacterium pseudotruncatum and has the highest similarity with Bifidobacterium DSM 20438 (T), which is 98.64%. The strain was preliminarily identified as Bifidobacterium pseudotruncatum. The strain B2479 was deposited in the Guangdong Provincial Microbiological Culture Collection Center on November 21, 2024, with the deposit number GDMCC No: 65515.

[0052] Example 2

[0053] Determination of the tolerance of Bifidobacterium pseudocatenulatum strain B24790 to gastrointestinal fluid

[0054] (1) Using a 1 mol / L NaHCO 3 The pH of artificial gastric juice was adjusted to 3.0±0.1. 1 mL of activated B24790 bacterial solution was added to 9 mL of artificial gastric juice, and 100 μL was taken for gradient dilution and viable bacteria count after thorough mixing. The rest was placed in 37°C anaerobic culture, and samples were taken for dilution and counting after 3 hours. The viable bacteria count at 0 hour was taken as 100% to calculate the survival rate. The results are shown in Table 1.

[0055] Table 1 In vitro tolerance of Bifidobacterium pseudocatenulatum strain B24790 to artificial gastric juice

[0056] Strain number 0h viable bacteria count (CFU / mL) 3h viable bacteria count (CFU / mL) Survival rate (%) B24790 <![CDATA[1.07×10 8 ]]> <![CDATA[0.68×10 8 ]]> 63.55

[0057] (2) Using a 1 mol / L Na hCO 3 The pH of the artificial intestinal fluid was adjusted to 8.0±0.1, 1 mL of the gastric juice from step (1) for 3 h was added to 9 mL of the artificial intestinal fluid, and after thorough mixing, the remainder was placed in anaerobic culture at 37°C. Samples were taken at 0, 2, 4, 6, and 8 h for dilution and coating, and the survival rate was calculated with the number of viable bacteria at 0 h as 100%. The results are shown in Table 2.

[0058] Table 2 In vitro tolerance of Bifidobacterium pseudocatenulatum strain B24790 to artificial intestinal fluid

[0059] Strain number 0h viable bacteria count (CFU / mL) 8h viable bacteria count (CFU / mL) Survival rate (%) B24790 <![CDATA[1.5×10 7 ]]> <![CDATA[9×10 6 ]]> 60.00

[0060] The results showed that the survival rate of Bifidobacterium pseudocatenulatum strain B24790 in artificial gastrointestinal fluid was over 60%, indicating that it has good tolerance to acidic and alkaline environments.

[0061] Example 3

[0062] Antimicrobial activity of Bifidobacterium pseudocatenulatum strain B24790 against clinical multidrug-resistant pathogens

[0063] The activation of Bifidobacterium pseudocatenulatum strain B24790 was carried out according to step (1) of Example 1. The activated Bifidobacterium pseudocatenulatum strain B24790 was inoculated into MPYG liquid culture medium and cultured for 24 hours, then centrifuged at 8000 r / min for 5 minutes to obtain a supernatant, which was dispensed into 50 mL centrifuge tubes and pre-frozen in a -80°C refrigerator, and then placed in a freeze dryer for freeze concentration after solidification. The concentrated sample was resuspended in sterile water.

[0064] Clinical drug-resistant bacteria Methicillin-resistant Staphylococcus aureus (MRSA), Extended-Spectrumβ-Lactamases (ESBL)-producing Escherichia coli, Acinetobacter baumannii HRAB-85, Pseudomonas aeruginosa PAO1 and Clostridium difficile were activated and inoculated into LB or MPYG solid culture medium at a 0.5% inoculum, mixed thoroughly and poured into culture dishes. After the culture medium cooled, a sterilized punch was used to punch holes, and 100 μL of concentrated supernatant resuspension was added to each hole. The blank group was replaced with sterile water. The anaerobic indicator culture medium was placed in an anaerobic workstation at 37°C for 1-2 days, and the aerobic indicator culture medium was placed in a constant temperature incubator at 37°C for overnight culture, and the size of the inhibition zone was recorded. The results are shown in Table 3.

[0065] Table 3 In vitro antibacterial activity of Bifidobacterium B24790

[0066] Indicator bacteria Diameter of inhibition zone (mm) Drug-resistant Staphylococcus aureus (MRSA) 22 ESBL-producing E. coli 15 Pseudomonas aeruginosa PAO1 (P. aeruginosa) 18.5 Acinetobacter baumannii hRAB-85 (A.baumannii) 15.5 Clostridium difficile 32

[0067] Figure 3 It shows that sterile water has no inhibitory effect on pathogens. Figure 4 The results showed that the fermentation supernatant concentrate of Bifidobacterium B24790 had a good inhibitory effect on the five indicator bacteria, indicating that Bifidobacterium B24790 has the potential to inhibit the activity of clinical multi-drug resistant pathogens in vitro.

[0068] Example 4

[0069] Antibiotic susceptibility test of Bifidobacterium pseudocatenulatum strain B24790

[0070] The activation of Bifidobacterium pseudocatenulatum strain B24790 was carried out according to step (1) of Example 1.

[0071] After the activated Bifidobacterium pseudomicrocystis strain B24790 was inoculated into MPYG liquid medium and cultured for 24 hours, it was inoculated into LB solid medium at 1% (v / v), shaken and poured onto a 90mm×90mm square bacterial culture plate, and used after cooling and solidification. A drug-sensitive sheet was attached to the surface of the culture medium, and two parallel copies of each drug-sensitive sheet were made, and placed in an anaerobic workstation at 37°C for 24 hours, and the inhibition zone was recorded.

[0072] like Figure 5 As shown in the figure, the drug sensitivity from AG is roxithromycin (15μg), ceftriaxone (30μg), ciprofloxacin (5μg), gentamicin (10μg), chloramphenicol (30μg), tetracycline (30μg) and ampicillin (10μg). The B24790 strain is only insensitive to ciprofloxacin, slightly sensitive to gentamicin, and most sensitive to chloramphenicol.

[0073] Example 5

[0074] Effects of Bifidobacterium pseudocatenulatus strain B24790 on LPS-induced secretion of inflammatory-related cytokines in RAW264.7 cells

[0075] After RAW264.7 cells were revived, they were plated at an inoculation volume of 500,000 per well. LPS was diluted with DMEM to a final concentration of 50 ng / mL. After the strain was activated and cultured, the supernatant was centrifuged and set aside. RAW264.7 cells were divided into the following three groups: blank group (1 mL DMEM, recorded as control), positive control group (1 mL DMEM containing LPS, recorded as LPS), supernatant group (0.5 mL fermentation supernatant concentrate + 0.5 mL DMEM containing LPSDMEM, recorded as B24790), each group was set up with 4 parallels, and the modeling time was 16 hours.

[0076] The concentrations of IL-6 and TNF-α in the cell culture supernatant were determined according to the instructions of the Jianglai ELISA kit.

[0077] like Figure 6 and Figure 7 The results showed that the pro-inflammatory factors in the culture fluid of RAW 264.7 cells stimulated by LPS increased significantly, while the B. pseudocatenulatus strain B24790 could significantly reduce the level of pro-inflammatory factors in RAW 264.7 cells stimulated by LPS. This result shows that the B. pseudocatenulatus strain B24790 has the potential to inhibit inflammation.

[0078] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A Bifidobacterium pseudosmall chain (Bifidobacterium umpseudocatenulatum) strain B24790, characterized in that The deposit number is GDMCC No:65515.

2. A metabolite or culture of the Bifidobacterium pseudocatenulatum strain B24790 according to claim 1.

3. A method for preparing the metabolites of the Bifidobacterium pseudocatenulatum strain B24790 according to claim 2, characterized in that: The following steps are involved: The activated Bifidobacterium pseudocatenulatum strain B24790 is inoculated into MPYG liquid medium for anaerobically culturing to obtain a culture; The liquid phase was separated from the culture to obtain metabolites of Bifidobacterium pseudocatenulatus strain B24790.

4. The preparation method according to claim 3, characterized in that: After separating the liquid phase, the method further comprises concentrating the liquid phase; the concentration multiple is 5 to 10 times.

5. A probiotic, characterized in that: The invention comprises the Bifidobacterium pseudocatenulatum strain B24790 according to claim 1, the metabolite or culture according to claim 2, or the metabolite of the Bifidobacterium pseudocatenulatum strain B24790 prepared by the preparation method according to claim 3 or 4.

6. Use of the Bifidobacterium pseudocatenulatum strain B24790 according to claim 1, the metabolite or culture according to claim 2, or the metabolite of the Bifidobacterium pseudocatenulatum strain B24790 prepared by the preparation method according to claim 3 or 4 in the preparation of a product for inhibiting clinical drug-resistant bacteria.

7. The use according to claim 6, characterized in that: The clinical drug-resistant bacteria include at least one of the following: Clostridium difficile, Acinetobacter baumannii, Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.

8. The use according to claim 6 or 7, characterized in that: The product includes at least one of the following: medicine, disinfected daily necessities, food, food additives, feed or feed additives.

9. Use of the Bifidobacterium pseudocatenulatum strain B24790 according to claim 1, the metabolite or culture according to claim 2, or the metabolite of the Bifidobacterium pseudocatenulatum strain B24790 prepared by the preparation method according to claim 3 or 4 in the preparation of anti-inflammatory drugs.

10. The use according to claim 9, characterized in that: The anti-inflammatory drug comprises at least one of the following dosage forms: tablets, powders, granules, capsules and oral solutions.

Images